Track market-moving stories before they get noisy

HRL's expertise in silicon-spin qubits and quantum sensing will strengthen and extend IBM's world-leading quantum computing mission

, /PRNewswire/ -- IBM (NYSE: IBM) today announced it has signed a definitive agreement to acquire HRL Laboratories, LLC (HRL), a flagship research and development institution. HRL is a private company jointly owned by Boeing and General Motors. Both Boeing and GM will continue to partner with IBM on quantum applications and advanced technology development following the transaction.

HRL's advanced expertise in silicon-spin qubit engineering will complement and extend IBM's long-term mission to scale increasingly powerful quantum computers and accelerate its quantum vision.  Superconducting qubits and spin qubits both leverage state-of-the art silicon fabrication. This shared foundation is amongst the reasons why these two modalities offer credible paths to scaling quantum technologies.

"The HRL team will help IBM push even farther forward toward the frontiers of quantum innovation," said Jay Gambetta, IBM's Director of Research and IBM Fellow. "This talented group of researchers brings a broad portfolio of technologies that will strengthen IBM's long-term plans to deliver useful quantum computing to the world, bringing together advances across quantum computing, quantum sensing, and quantum networking to enable the applications of the future." 

"Joining IBM is the natural next chapter for what we have built at HRL, where our team has dedicated years to exploring paths to how future quantum computers could be built at scales that today seem impossible," said Rob Vasquez, President and Chief Executive Officer at HRL "We now look forward to leveraging IBM's industry leadership and working alongside their world-class talent on fundamental infrastructure to take this vision forward. Additionally, our cutting-edge physical and information science innovations will combine with their advanced research capabilities to deliver an unmatched suite of technology solutions for our commercial and government customers."

HRL will also enable IBM to innovate in and industrialize promising technologies such as quantum sensing and drive new research into quantum materials. This includes ultra precise quantum sensors capable of detecting subtle physical phenomena and capturing finely tuned measurements for life sciences, navigation, defense, and scientific applications. Combined with additional capabilities in cryogenics, control electronics, qubit interconnects, and packaging, IBM anticipates that HRL's technical breakthroughs will help fuel its quantum program for decades to come.

Additionally, HRL has developed innovations in novel quantum materials that have the potential to unlock better semiconductors and more sensitive sensors – all of which can optimize the performance and scalability of a wide range of quantum technologies.

Beyond its leadership in quantum computing, HRL brings deep expertise in advanced sensors, high-speed and high-power communications, electronics, advanced manufacturing, and materials science, developed through decades of research and development for both commercial and U.S. government customers. HRL's broad technology portfolio will complement IBM's innovation leadership and help accelerate the development of next-generation computing, communications, and mission-critical systems.

Advancing Quantum Computers for Generations to Come

IBM continues to define the direction for the industry with superconducting qubit-based architectures, including breakthroughs in error correction and new algorithms enabling quantum computers to run harder problems more efficiently. IBM's roadmap to deliver the world's first large-scale, fault-tolerant quantum computers is clear and on course. This includes delivering IBM Quantum Starling by 2029, which will be 20,000 times more powerful than today's quantum computers and capable of running 100 million quantum operations. In the mid-2030s, Starling will be followed by the even more powerful Blue Jay quantum computer, projected to be capable of 1 billion quantum operations.

As IBM looks to further extend quantum computing, HRL will bring robust knowledge of silicon‑based spin qubit platforms and surrounding infrastructure that could offer new insights into how to best scale quantum computers into the next decade.

In May 2026, IBM further expanded its global quantum leadership when the company announced it would establish Anderon, the world's first pure-play quantum wafer foundry. As a standalone IBM company, Anderon is being created with the support of the U.S. Department of Commerce to enable scalable, consistent, and agile manufacturing for a broad range of quantum computing modalities and companies. The acquisition of HRL offers an opportunity to partner even more closely with Anderon, including potential plans to develop spin qubit manufacturing to scale quantum manufacturing and enable faster learning cycles.

Financial details of the transaction were not disclosed, and IBM's acquisition of HRL is subject to customary closing conditions and regulatory approvals. The transaction is anticipated to close by the end of the third quarter of 2026.

Media Contact:
Erin Angelini
IBM
[email protected] 

SOURCE IBM

Posted by Defense World Staff on Jul 23rd, 2026

American Investment Services Inc. purchased a new stake in UnitedHealth Group Incorporated (NYSE:UNH – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,802 shares of the healthcare conglomerate’s stock, valued at approximately $1,029,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Sarver Vrooman Wealth Advisors purchased a new stake in shares of UnitedHealth Group in the 4th quarter valued at approximately $25,000. Beacon Financial Strategies CORP acquired a new stake in shares of UnitedHealth Group in the fourth quarter worth $26,000. Anfield Capital Management LLC raised its position in UnitedHealth Group by 220.0% during the fourth quarter. Anfield Capital Management LLC now owns 80 shares of the healthcare conglomerate’s stock valued at $26,000 after buying an additional 55 shares during the period. Joseph Group Capital Management purchased a new stake in UnitedHealth Group in the 4th quarter worth about $27,000. Finally, Nalls Sherbakoff Group LLC purchased a new position in UnitedHealth Group during the 4th quarter valued at about $27,000. 87.86% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting UnitedHealth Group Here are the key news stories impacting UnitedHealth Group this week:

Positive Sentiment: Analysts and market-watchers highlighted improving earnings estimates for UnitedHealth, with Zacks upgrading UNH to a Strong Buy and noting that rising consensus forecasts could support more upside. Will UnitedHealth (UNH) Gain on Rising Earnings Estimates? Positive Sentiment: JPMorgan raised its price target on UNH to $516 and kept an overweight rating, signaling continued confidence in the company’s turnaround and earnings power. UnitedHealth Group had its price target raised by JPMorgan Chase & Co. Positive Sentiment: Recent commentary also pointed to strong quarterly results, raised guidance, and a $5 billion buyback authorization as catalysts that could support further gains in UNH. A $5 Billion Reason to Buy UnitedHealth Stock Here Positive Sentiment: UNH was also featured as a dividend and defensive healthcare name, reinforcing investor demand for stable cash flow and lower-volatility exposure. UnitedHealth Stock: Is It Headed for $500? Neutral Sentiment: CNBC’s “Final Trades” mention added visibility to UNH, but the item did not include a specific new thesis or company-specific development. Nvidia, Goldman Sachs, UnitedHealth and an Energy Stock on CNBC’s ‘Final Trades’ Negative Sentiment: Some analysts cautioned that UNH’s rebound may not be linear and could face near-term consolidation, suggesting investors may see pauses or pullbacks even within a broader recovery. UnitedHealth: Recovery Unlikely To Be Linear – Near-Term Consolidation Risks Negative Sentiment: Broader healthcare commentary also noted skepticism around the sector’s AI story, which may weigh on sentiment for some healthcare names if investors view the narrative as overstated. Fishbone Advisors Survey: Institutional Investors See Healthcare’s AI Story as Overblown UnitedHealth Group Stock Down 1.1% UnitedHealth Group stock opened at $431.68 on Thursday. The company has a market capitalization of $392.02 billion, a P/E ratio of 27.78, a P/E/G ratio of 1.52 and a beta of 0.62. UnitedHealth Group Incorporated has a 1-year low of $234.60 and a 1-year high of $461.62. The firm’s fifty day simple moving average is $406.97 and its 200-day simple moving average is $344.46. The company has a current ratio of 0.78, a quick ratio of 0.80 and a debt-to-equity ratio of 0.66.

UnitedHealth Group (NYSE:UNH – Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare conglomerate reported $6.38 EPS for the quarter, topping the consensus estimate of $4.94 by $1.44. The firm had revenue of $112.03 billion for the quarter, compared to the consensus estimate of $110.81 billion. UnitedHealth Group had a net margin of 3.14% and a return on equity of 16.53%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business posted $4.08 earnings per share. UnitedHealth Group has set its FY 2026 guidance at 19.500-20.000 EPS. Sell-side analysts forecast that UnitedHealth Group Incorporated will post 19.65 earnings per share for the current fiscal year.

UnitedHealth Group Increases Dividend The business also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 15th were given a dividend of $2.32 per share. The ex-dividend date of this dividend was Monday, June 15th. This is an increase from UnitedHealth Group’s previous quarterly dividend of $2.21. This represents a $9.28 dividend on an annualized basis and a yield of 2.1%. UnitedHealth Group’s dividend payout ratio (DPR) is currently 59.72%.

Analyst Upgrades and Downgrades UNH has been the subject of several research reports. Oppenheimer raised their price target on shares of UnitedHealth Group from $420.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Mizuho increased their target price on shares of UnitedHealth Group from $470.00 to $493.00 and gave the stock an “outperform” rating in a research report on Monday. HC Wainwright set a $492.00 price target on shares of UnitedHealth Group in a report on Wednesday, May 27th. Barclays increased their price objective on UnitedHealth Group from $429.00 to $441.00 and gave the stock an “overweight” rating in a report on Monday. Finally, DA Davidson set a $512.00 target price on UnitedHealth Group in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $455.92.

Get Our Latest Research Report on UNH

About UnitedHealth Group (Free Report)

UnitedHealth Group Inc is a diversified health care company headquartered in Minnetonka, Minnesota, that operates two primary business platforms: UnitedHealthcare and Optum. Founded in 1977, the company provides a broad range of health benefits and health care services to individuals, employers, governmental entities and other organizations. Its operations span commercial employer-sponsored plans, individual and Medicare and Medicaid programs, and services for customers and health systems in the United States and selected international markets.

UnitedHealthcare is the company’s benefits business, administering health plans and networks, managing provider relationships, and offering coverage products for employers, individuals, and government-sponsored programs.

See Also Five stocks we like better than UnitedHealth Group Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH – Free Report).

Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of New York Mellon Corp Sells 2,889 Shares of FirstCash Holdings, Inc. $FCFS

NEXT HEADLINE »Marsh & McLennan Companies (NYSE:MRSH) Price Target Raised to $201.00 at Mizuho

Electronic Arts and PIF (Public Investment Fund) logos are seen in this illustration taken September 30, 2025. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab

CompaniesBRUSSELS, July 23 (Reuters) - A group of investors including Saudi Arabia's Public Investment Fund ​has secured EU antitrust approval for ‌its $55 billion acquisition of video game developer Electronic Arts (EA.O), opens new tab, the European Commission said on Thursday.

Saudi ​Arabia's $1 trillion wealth fund, Jared ​Kushner's Affinity Partners and private equity ⁠firm Silver Lake announced the deal, ​the largest leveraged buyout in history, in ​September last year.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The Commission, which acts as the EU competition enforcer and had examined the ​deal under its merger rules, said ​the acquisition would not raise competition concerns, confirming a Reuters ‌story.

The ⁠EU executive is also scrutinising the deal under its Foreign Subsidies Regulation (FSR) aimed at preventing unfair non-EU subsidies granted ​to companies ​looking ⁠to acquire rivals in the 27-country bloc and is seen ​as a bigger hurdle.

PIF is ​also expected ⁠to win EU clearance under EU subsidy rules, people familiar with the matter ⁠told ​Reuters last week. The ​Commission's decision is due by July 30.

Reporting by Foo ​Yun Chee; Editing by K irsten Donovan

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Posted by Defense World Staff on Jul 23rd, 2026

AR Asset Management Inc. raised its position in Chevron Corporation (NYSE:CVX – Free Report) by 5.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 119,618 shares of the oil and gas company’s stock after purchasing an additional 6,254 shares during the period. Chevron accounts for approximately 4.8% of AR Asset Management Inc.’s portfolio, making the stock its 2nd biggest holding. AR Asset Management Inc.’s holdings in Chevron were worth $24,749,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Cornerstone Advisory LLC boosted its stake in Chevron by 0.9% during the first quarter. Cornerstone Advisory LLC now owns 5,625 shares of the oil and gas company’s stock worth $1,164,000 after buying an additional 52 shares during the last quarter. Compton Financial Group LLC grew its holdings in Chevron by 1.9% in the 1st quarter. Compton Financial Group LLC now owns 2,944 shares of the oil and gas company’s stock valued at $609,000 after buying an additional 56 shares in the last quarter. Quantum Portfolio Management LLC increased its stake in shares of Chevron by 2.7% in the 1st quarter. Quantum Portfolio Management LLC now owns 2,101 shares of the oil and gas company’s stock worth $435,000 after acquiring an additional 56 shares during the last quarter. D.B. Root & Company LLC increased its stake in shares of Chevron by 1.0% in the 4th quarter. D.B. Root & Company LLC now owns 5,552 shares of the oil and gas company’s stock worth $846,000 after acquiring an additional 57 shares during the last quarter. Finally, Chatterton & Associates Inc. raised its holdings in shares of Chevron by 1.7% during the 1st quarter. Chatterton & Associates Inc. now owns 3,427 shares of the oil and gas company’s stock worth $652,000 after acquiring an additional 57 shares during the period. Institutional investors and hedge funds own 72.42% of the company’s stock.

Chevron Stock Up 1.0% Shares of Chevron stock opened at $193.04 on Thursday. Chevron Corporation has a 52-week low of $146.49 and a 52-week high of $214.71. The company has a 50 day moving average of $181.88 and a 200 day moving average of $183.48. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $384.45 billion, a P/E ratio of 33.46, a P/E/G ratio of 0.67 and a beta of 0.50.

Chevron (NYSE:CVX – Get Free Report) last released its quarterly earnings data on Friday, May 1st. The oil and gas company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.41. The business had revenue of $47.56 billion during the quarter, compared to analysts’ expectations of $51.86 billion. Chevron had a net margin of 5.79% and a return on equity of 6.90%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.18 EPS. As a group, research analysts forecast that Chevron Corporation will post 14.78 EPS for the current fiscal year.

Chevron Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Tuesday, May 19th were issued a dividend of $1.78 per share. This represents a $7.12 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date of this dividend was Tuesday, May 19th. Chevron’s payout ratio is 123.40%.

Insider Transactions at Chevron In other news, Director John B. Hess sold 380,000 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was sold at an average price of $193.20, for a total transaction of $73,416,000.00. Following the completion of the transaction, the director directly owned 278,045 shares of the company’s stock, valued at approximately $53,718,294. This represents a 57.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.56% of the stock is owned by company insiders.

Key Headlines Impacting Chevron Here are the key news stories impacting Chevron this week:

Positive Sentiment: TD Cowen lifted its price target on Chevron to $200 from $197, signaling continued analyst confidence despite keeping a hold rating. TD Cowen price target update Positive Sentiment: Chevron is being highlighted in dividend-focused articles as a steady income name, which may support demand from long-term investors. Dividend Aristocrats article Positive Sentiment: Rising oil prices amid geopolitical uncertainty are favorable for Chevron’s upstream business and could improve near-term earnings. Oil prices jump article Neutral Sentiment: Chevron shut production at a U.S. Gulf platform ahead of a tropical storm, a precautionary move that could limit output temporarily but is not necessarily a lasting operational issue. Production shutdown article Neutral Sentiment: Investors are awaiting Chevron’s second-quarter earnings, with expectations for a strong profit rebound; the report could become a major stock catalyst. Earnings preview article Analysts Set New Price Targets Several equities research analysts recently issued reports on CVX shares. Sanford C. Bernstein cut their price objective on shares of Chevron from $216.00 to $204.00 and set a “market perform” rating for the company in a research report on Monday, May 11th. Weiss Ratings downgraded shares of Chevron from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, June 2nd. Royal Bank Of Canada restated an “outperform” rating and set a $220.00 price target on shares of Chevron in a report on Tuesday, May 5th. Wolfe Research raised shares of Chevron from a “peer perform” rating to an “outperform” rating and set a $210.00 price target on the stock in a research report on Thursday, July 2nd. Finally, Zacks Research lowered Chevron from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Nineteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $206.62.

Get Our Latest Stock Report on Chevron

Chevron Company Profile (Free Report)

Chevron Corporation (NYSE: CVX) is an American multinational energy company engaged in virtually all aspects of the oil and gas industry. As an integrated energy firm, Chevron’s core activities include upstream oil and natural gas exploration and production, midstream transportation and storage, downstream refining and marketing of fuels and lubricants, and petrochemical manufacturing through joint ventures and subsidiaries. The company markets fuels under brands such as Chevron, Texaco and Caltex and supplies a range of products and services to retail customers, industrial users and commercial fleets worldwide.

Chevron traces its corporate lineage to the early petroleum companies that eventually became Standard Oil of California and has evolved through significant mergers and restructurings, including the acquisitions of Gulf Oil and Texaco.

Further Reading Five stocks we like better than Chevron Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Chevron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chevron and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAssetmark Inc. Lowers Stock Holdings in Axon Enterprise, Inc $AXON

NEXT HEADLINE »ABN Amro Investment Solutions Buys 3,147 Shares of Phillips 66 $PSX

Alamar Capital Management LLC purchased a new position in shares of Caterpillar Inc. (NYSE:CAT – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,000 shares of the industrial products company’s stock, valued at approximately $708,000.

A number of other institutional investors also recently added to or reduced their stakes in CAT. Diamant Asset Management Inc. grew its position in Caterpillar by 68,427.2% during the first quarter. Diamant Asset Management Inc. now owns 3,140,603 shares of the industrial products company’s stock worth $2,224,992,000 after buying an additional 3,136,020 shares during the period. Capital International Investors purchased a new stake in shares of Caterpillar during the 4th quarter worth approximately $1,225,317,000. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Caterpillar by 573.1% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,504,612 shares of the industrial products company’s stock worth $861,947,000 after acquiring an additional 1,281,087 shares during the period. Bank of America Corp DE increased its stake in Caterpillar by 16.0% in the 4th quarter. Bank of America Corp DE now owns 6,738,802 shares of the industrial products company’s stock valued at $3,860,457,000 after purchasing an additional 928,974 shares in the last quarter. Finally, Cynosure Group LLC increased its stake in Caterpillar by 8,359.6% in the 4th quarter. Cynosure Group LLC now owns 513,754 shares of the industrial products company’s stock valued at $294,314,000 after purchasing an additional 507,681 shares in the last quarter. Hedge funds and other institutional investors own 70.98% of the company’s stock.

Insider Transactions at Caterpillar In other Caterpillar news, CFO Andrew R. J. Bonfield sold 15,674 shares of the business’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $918.71, for a total value of $14,399,860.54. Following the completion of the transaction, the chief financial officer directly owned 52,935 shares in the company, valued at approximately $48,631,913.85. The trade was a 22.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Lange Bob De sold 24,222 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $922.92, for a total transaction of $22,354,968.24. Following the transaction, the insider directly owned 86,029 shares of the company’s stock, valued at approximately $79,397,884.68. This represents a 21.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 95,773 shares of company stock worth $87,642,635 in the last three months. 0.33% of the stock is currently owned by company insiders.

Caterpillar News Roundup Here are the key news stories impacting Caterpillar this week:

Positive Sentiment: Analysts have been raising their outlook on Caterpillar, with one report saying the stock’s fair value estimate was lifted to $970.37 as investors continue to focus on strong demand in construction, energy, data centers, and infrastructure. Caterpillar Stock Fair Value Edges Higher After Analysts Lift Targets Positive Sentiment: Caterpillar was highlighted in several pieces as a stock with AI exposure and reliable dividend growth, which can attract investors looking for both growth and defensive characteristics. These Stocks Offer AI Exposure and Dividend Payouts Positive Sentiment: The company is also being discussed as a “solid defensive play” thanks to its long dividend-increase streak and stable yield, which may help support the stock during uncertain markets. A Boring Dividend Growth Strategy Becomes a Solid Defensive Play (CAT) Positive Sentiment: Caterpillar also announced it will release second-quarter 2026 results on August 4, keeping attention on upcoming earnings that could provide another catalyst for the shares. Caterpillar Inc. to Announce Second-Quarter 2026 Financial Results on August 4 Neutral Sentiment: A local article noted Caterpillar is renovating a recently purchased Texas property, which appears to be a routine real-estate and facilities update rather than a major stock-moving event. Caterpillar embarks on renovations after purchasing property in Texas Analyst Upgrades and Downgrades A number of analysts have commented on CAT shares. Barclays boosted their target price on Caterpillar from $700.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Oppenheimer lifted their price target on Caterpillar from $980.00 to $1,105.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Argus boosted their price objective on shares of Caterpillar from $820.00 to $990.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Evercore reissued an “outperform” rating and issued a $1,103.00 price objective on shares of Caterpillar in a research note on Monday, May 11th. Finally, Rothschild & Co Redburn lifted their target price on shares of Caterpillar from $700.00 to $950.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Fifteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $980.57.

Read Our Latest Report on CAT

Caterpillar Stock Down 0.0% Shares of NYSE:CAT opened at $889.79 on Thursday. The company has a quick ratio of 0.81, a current ratio of 1.35 and a debt-to-equity ratio of 1.64. The company has a market capitalization of $409.83 billion, a P/E ratio of 44.29, a P/E/G ratio of 1.74 and a beta of 1.57. Caterpillar Inc. has a 52-week low of $405.46 and a 52-week high of $1,073.46. The stock’s fifty day simple moving average is $929.39 and its 200-day simple moving average is $801.45.

Caterpillar (NYSE:CAT – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The industrial products company reported $5.54 EPS for the quarter, topping analysts’ consensus estimates of $4.65 by $0.89. The firm had revenue of $17.41 billion during the quarter, compared to analysts’ expectations of $16.53 billion. Caterpillar had a return on equity of 48.21% and a net margin of 13.33%.The firm’s quarterly revenue was up 22.2% compared to the same quarter last year. During the same quarter last year, the business posted $4.25 EPS. As a group, equities research analysts forecast that Caterpillar Inc. will post 24.87 earnings per share for the current fiscal year.

Caterpillar Increases Dividend The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 19th. Investors of record on Monday, July 20th will be given a dividend of $1.63 per share. This represents a $6.52 dividend on an annualized basis and a yield of 0.7%. This is an increase from Caterpillar’s previous quarterly dividend of $1.51. The ex-dividend date is Monday, July 20th. Caterpillar’s dividend payout ratio (DPR) is 32.45%.

Caterpillar Profile (Free Report)

Caterpillar Inc is a global manufacturer of construction and mining equipment, diesel and natural gas engines, industrial gas turbines and locomotives. The company’s product portfolio includes earthmoving machines such as excavators, bulldozers, wheel loaders and off‑highway trucks, as well as a range of power generation products including generator sets and power systems for industrial and commercial use. Caterpillar serves customers across heavy construction, mining, energy, transportation and related industries with both equipment and integrated technology solutions.

In addition to manufacturing, Caterpillar provides a broad range of aftermarket parts and support services, including maintenance, repair, remanufacturing and fleet management tools.

See Also Five stocks we like better than Caterpillar Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Caterpillar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caterpillar and related companies with MarketBeat.com's FREE daily email newsletter.

TORONTO, July 23, 2026 /PRNewswire/ -- Mayfair Gold Corp. ("Mayfair", "Mayfair Gold", or the "Company") (TSXV: MFG) (NYSE American: MINE) is pleased to provide a progress update on activities completed during Q2 2026 and ongoing key work streams to advance and de-risk the Company's 100% controlled Fenn-Gib Gold Project ("Fenn-Gib" or the "Project") in Northern Ontario. Key Highlights: Engineering & Design: Advancing front-end engineering design with Ausenco leading plant engineering, and site layout work for the planned 4,800 tonne-per-day process plant Grade Control Drilling: Concluded the grade control drilling program, which confirmed Resource model confidence and identified upside in higher-grade material Environmental Work and Advancing Permitting: Progressing environmental baseline studies and preparing the Ontario-led One Project, One Process environmental approval submission Infrastructure: Advanced powerline planning and engagement with HONI and IESO, while progressing site access options; advanced condemnation drilling review and geotechnical investigations for key infrastructure and plant site locations Exploration: Advancing compilation, mapping and prospecting across the expanded regional land package Capital Markets: Initiated early engagement with potential project financing parties Planned Activities for Q3: Plans to complete process plant FEED and tender detailed engineering, advance the 1P1P submissions and project financing discussions, and further de-risk earthworks, tailings storage facility and water management designs Drew Anwyll, P.Eng.

, /PRNewswire/ -- ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company"), a leading and fast-growing express delivery company in China, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2026 and its unaudited interim financial results for the half year ended June 30, 2026, after the U.S. market closes on August 18, 2026.

ZTO's management team will host an earnings conference call at 8:30 P.M. U.S. Eastern Time on Tuesday, August 18, 2026, which is 8:30 A.M. Beijing Time on Wednesday, August 19, 2026.

Dial-in details for the earnings conference call are as follows:

United States/Canada:

1-888-317-6003

Hong Kong:

800-963976

Mainland China:

4001-206115

International:

1-412-317-6061

Passcode:

1904847

A replay of the conference call may be accessible through August 24, 2026 by dialing the following numbers:

United States/Canada:

1-855-669-9658

International:

1-412-317-0088

Passcode:

8514365

A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://zto.investorroom.com.

About ZTO Express (Cayman) Inc.

ZTO Express (Cayman) Inc. (NYSE: ZTO and SEHK: 2057) ("ZTO" or the "Company") is a leading and fast-growing express delivery company in China. ZTO provides express delivery service as well as other value-added logistics services through its extensive and reliable nationwide network coverage in China.

ZTO operates a highly scalable network partner model, which the Company believes is best suited to support the significant growth of e-commerce in China. The Company leverages its network partners to provide pickup and last-mile delivery services, while controlling the mission-critical line-haul transportation and sorting network within the express delivery service value chain.

For more information, please visit http://zto.investorroom.com.

For investor inquiries, please contact:

Investor Relations
Tel: (86) 21 5980 4508
Email: [email protected]

SOURCE ZTO Express (Cayman) Inc.

BELLEVUE, Wash.--(BUSINESS WIRE)--T-Mobile US, Inc. (NASDAQ: TMUS): Continued Strong Account Growth and Deepening Customer Relationships Fueled by Widening Differentiation Postpaid Average Revenue Per Account (“ARPA”) of $152.91 grew 2% year-over-year Postpaid net account additions of 277 thousand decreased 13% year-over-year Translating Strong Account Growth into Durable and Profitable Financial Growth Service revenues of $19.0 billion grew 9% year-over-year, industry-leading growth(1) Postpai.

HomeIndustriesTelecommunicationsEarnings ResultsEarnings ResultsThe wireless carrier has focused on amassing ‘higher quality accounts’ after introducing new plans last yearJuly 23, 2026, 6:39 a.m. ET

T-Mobile reported a profit beat for the second quarter. Photo: Joe Raedle/Getty ImagesT-Mobile just raised its cash-flow guidance for the year after what its CFO called a “rinse-and-repeat” quarter of positive performance.

Second-quarter profit surpassed the consensus view, with T-Mobile TMUS posting $3.2 billion on the bottom line, or $2.99 in earnings per share. That was up 5% from a year before and ahead of FactSet consensus expectations for $2.59 in EPS.

, /PRNewswire/ -- Dow (NYSE: DOW): 

FINANCIAL HIGHLIGHTS

Net sales were $12.1 billion, up 20% year-over-year, reflecting increases in all operating segments and regions. Local price increased 20% versus the year-ago period, led by gains in Packaging & Specialty Plastics, with higher polyethylene prices in all regions. Currency increased 1% year-over-year. Volume decreased 1% year-over-year. Gains in Performance Materials & Coatings across both businesses were more than offset by declines in Packaging & Specialty Plastics largely due to planned maintenance activity.   GAAP net income was $802 million. Op. EBIT1 was $1.6 billion, up $1.7 billion year-over-year, primarily driven by higher prices as well as the Company's self-help initiatives. GAAP earnings per share (EPS) was $0.99; operating EPS1 was $1.44, compared to a loss of $0.42 in the year-ago period. Op. EPS excludes significant items totaling $0.45 per share, driven by costs associated with Transform to Outperform, partially offset by an income tax adjustment associated with a payment from NOVA Chemicals.   Cash provided by operating activities – continuing operations was $1.3 billion, primarily driven by higher earnings across all businesses, more than offsetting an expected working capital build reflecting revenue growth.   Returns to shareholders totaled $253 million of dividends in the quarter. CEO QUOTE

"Team Dow delivered strong second quarter results through disciplined and timely execution, reliably serving our customers, and accelerating our self-help actions," said Karen S. Carter, Dow CEO. "Market conditions were supportive this quarter, and our self-help initiatives delivered ahead of plan, further reinforcing the improvement in our earnings as we continue to strengthen Dow's resilience and agility. We now expect to generate approximately $200 million more in benefits from Transform to Outperform this year, enabling us to increase the total in-year benefits from self-help to greater than $1.3 billion. Our actions to become a leaner, more competitive company position Dow well to continue winning with our customers while delivering enhanced long-term shareholder value."

SUMMARY FINANCIAL RESULTS

Three Months Ended Jun 30

In millions, except per share amounts

2Q26

2Q25

vs. SQLY

[B / (W)]

Net Sales

$12,092

$10,104

$1,988

GAAP Income (Loss) Net of Tax

$802

$(801)

$1,603

Operating EBIT¹

$1,648

$(21)

$1,669

Operating EBITDA¹

$2,312

$703

$1,609

GAAP Earnings (Loss) Per Share

$0.99

$(1.18)

$2.17

Operating Earnings Per Share¹

$1.44

$(0.42)

$1.86

Cash Provided by (Used for) Operating Activities
– Cont. Ops

$1,324

$(470)

$1,794

1. Op. Earnings Per Share, Op. EBIT, Op. EBIT Margin and Op. EBITDA, Free Cash Flow and Cash Flow Conversion are non-GAAP measures. See appendix for further discussion.
®TM Trademark of The Dow Chemical Company or an affiliated company of Dow 

SEGMENT HIGHLIGHTS

Packaging & Specialty Plastics

Three Months Ended Jun 30

In millions

2Q26

2Q25

vs. SQLY

[B / (W)]

Net Sales

$6,385

$5,025

$1,360

Operating EBIT

$1,278

$71

$1,207

Packaging & Specialty Plastics segment net sales in the quarter were $6.4 billion, up 27% versus the year-ago period. Local price increased 30% year-over-year, primarily driven by higher polyethylene prices in all regions. Currency increased net sales by 1%. Volume decreased 4% year-over-year, driven by lower volumes in both businesses, including higher planned maintenance activity in Hydrocarbons & Energy, resulting in lower merchant sales.  

Op. EBIT was $1.3 billion, an increase of $1.2 billion compared to the year-ago period, driven by higher integrated margins as a result of higher polyethylene prices contributing to margin expansion and tailwinds from the Company's self-help initiatives, which were partly offset by higher planned maintenance activity.

Packaging and Specialty Plastics business reported a net sales increase versus the year-ago period, reflecting higher polyethylene prices, most notably in flexible packaging applications and in all regions. This more than offset lower polyethylene volumes, driven by declines in Europe, the Middle East, Africa and India (EMEAI) and Asia Pacific impacted by the Middle East conflict.

Hydrocarbons & Energy business reported a net sales increase year-over-year, driven by higher olefins prices, which more than offset lower volumes due to planned maintenance activity in the U.S. Gulf Coast and the idling of a cracker in EMEAI in mid-2025, which successfully restarted in June.

Industrial Intermediates & Infrastructure

Three Months Ended Jun 30

In millions

2Q26

2Q25

vs. SQLY

[B / (W)]

Net Sales

$3,166

$2,786

$380

Operating EBIT

$246

$(185)

$431

Industrial Intermediates & Infrastructure segment net sales in the quarter were $3.2 billion, up 14% versus the year-ago period. Local price increased 15% year-over-year, reflecting gains in both businesses and in all regions. Currency increased net sales by 1%. Volume decreased 2% year-over-year, driven by lower volumes in Polyurethanes & Construction Chemicals, including impacts from the Middle East conflict, which were partially offset by increased volume in Industrial Solutions. 

Op. EBIT was $246 million, an increase of $431 million versus the year-ago period, driven by higher margins, tailwinds from the Company's self-help initiatives, lower planned maintenance activity and the suspension of the recognition of equity losses from Sadara.

Polyurethanes & Construction Chemicals business reported an increase in net sales compared to the year-ago period, primarily driven by local price gains, which were partly offset by lower volumes. Volume growth across industrial market applications was more than offset by impacts from the Middle East conflict.

Industrial Solutions business reported an increase in net sales, with local price gains in all regions compared to the year-ago period. Volume growth was driven by recent alkoxylation investments and increased demand for data center applications, partially offset by impacts from the Middle East conflict.

Performance Materials & Coatings

Three Months Ended Jun 30

In millions

2Q26

2Q25

vs. SQLY

[B / (W)]

Net Sales

$2,361

$2,129

$232

Operating EBIT

$133

$152

($19)

Performance Materials & Coatings segment net sales in the quarter were $2.4 billion, up 11% versus the year-ago period. Local price increased 4% year-over-year, driven by an increase in Coatings & Performance Monomers. Currency increased net sales by 1%. Volume increased 6% year-over-year, driven by higher volumes in both businesses, led by growth in downstream silicones.  

Op. EBIT was $133 million, a decrease of $19 million versus the year-ago period, as tailwinds from the Company's self-help initiatives were more than offset by higher fixed costs, including turnaround activity in the quarter and the costs associated with the in-period shutdown of our Barry, U.K. upstream siloxanes plant.

Consumer Solutions business reported an increase in net sales versus the year-ago period, driven by volume gains in downstream silicones, led by consumer, electronics and home care applications.

Coatings & Performance Monomers business reported an increase in net sales across all regions compared to the year-ago period, led by higher price and volume in both acrylic monomers and architectural coatings.

OUTLOOK

"As we look into the second half of 2026, we will continue to build a more agile and resilient company that sets a new competitive standard," said Carter. "We will do so by advancing three priorities: growth and innovation in attractive end markets, investing in and strengthening our portfolio, and ensuring balanced capital allocation. Aligned to this, Transform to Outperform is delivering improvements in both growth and productivity, and we expect the impact of these efforts to ramp significantly throughout the remainder of this year and into 2027. Taken together, our collective actions are focused on enhancing the long-term value Dow delivers across the cycle."

Conference Call
Dow will host a live webcast of its quarterly earnings conference call with investors to discuss its results, business outlook and other matters today at 8:00 a.m. ET. The webcast and slide presentation that accompany the conference call will be posted on the events and presentations page of investors.dow.com.

About Dow
Dow (NYSE: DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, customer-focused innovation and leading business positions enable us to achieve profitable growth and help deliver a sustainable future. We operate manufacturing sites in 29 countries and employed approximately 34,600 people as of year-end 2025. Dow delivered sales of approximately $40 billion in 2025. References to Dow or the Company mean Dow Inc. and its subsidiaries. Learn more about us at www.dow.com.

X: https://twitter.com/DowNewsroom 
Facebook: https://www.facebook.com/dow/ 
LinkedIn: http://www.linkedin.com/company/dow-chemical 
Instagram: http://instagram.com/dow_official 

Cautionary Statement about Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements often address expected future business and financial performance, financial condition, and other matters, and often contain words or phrases such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "opportunity," "outlook," "plan," "project," "seek," "should," "strategy," "target," "will," "will be," "will continue," "will likely result," "would" and similar expressions, and variations or negatives of these words or phrases.

Forward-looking statements are based on current assumptions and expectations of future events that are subject to risks, uncertainties and other factors that are beyond Dow's control, which may cause actual results to differ materially from those projected, anticipated or implied in the forward-looking statements and speak only as of the date the statements were made. These factors include, but are not limited to: sales of Dow's products; Dow's expenses, future revenues and profitability; any supply chain, operational or other disruptions, sanctions, export restrictions, or increased economic uncertainty related to the ongoing conflicts between Russia and Ukraine and in the Middle East; capital requirements and need for and availability of financing; unexpected barriers in the development of technology, including with respect to Dow's contemplated capital and operating projects; Dow's ability to realize its commitment to carbon neutrality on the contemplated timeframe, including the completion and success of its integrated ethylene cracker and derivatives facility in Alberta, Canada; size of the markets for Dow's products and services and ability to compete in such markets; Dow's ability to develop and market new products and optimally manage product life cycles; the rate and degree of market acceptance of Dow's products; significant litigation and environmental matters and related contingencies and unexpected expenses; the success of competing technologies that are or may become available; the ability to protect Dow's intellectual property in the United States and abroad; Dow's ability to realize expected benefits from Transform to Outperform on the contemplated timeframe; developments related to contemplated restructuring activities and proposed divestitures or acquisitions such as workforce reduction, manufacturing facility and/or asset closure and related exit and disposal activities, and the benefits and costs associated with each of the foregoing; fluctuations in energy and raw material prices; management of process safety and product stewardship; changes in relationships with Dow's significant customers and suppliers; changes in public sentiment and political leadership; increased concerns about plastics in the environment and lack of a circular economy for plastics at scale; changes in consumer preferences and demand; changes in laws and regulations, political conditions, tariffs and trade policies, or industry development; global economic and capital markets conditions, such as inflation, market uncertainty, interest and currency exchange rates, and equity and commodity prices; business, logistics, and supply disruptions; security threats, such as acts of sabotage, terrorism or war, including the ongoing conflicts between Russia and Ukraine and in the Middle East; weather events and natural disasters; disruptions in Dow's information technology networks and systems, including the impact of cyberattacks; risks related to Dow's separation from DowDuPont Inc. such as Dow's obligation to indemnify DuPont de Nemours, Inc. and/or Corteva, Inc. for certain liabilities; and any global and regional economic impacts of a pandemic or other public health-related risks and events on Dow's business.

Where, in any forward-looking statement, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. A detailed discussion of principal risks and uncertainties which may cause actual results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and the Company's subsequent reports filed with the U.S. Securities and Exchange Commission. These are not the only risks and uncertainties that Dow faces. There may be other risks and uncertainties that Dow is unable to identify at this time or that Dow does not currently expect to have a material impact on its business. If any of those risks or uncertainties develops into an actual event, it could have a material adverse effect on Dow's business. Dow Inc. and The Dow Chemical Company and its consolidated subsidiaries assume no obligation to update or revise publicly any forward-looking statements whether because of new information, future events, or otherwise, except as required by securities and other applicable laws.

®TM Trademark of The Dow Chemical Company or an affiliated company of Dow                 

Non-GAAP Financial Measures
This earnings release includes information that does not conform to GAAP and are considered non-GAAP measures. Management uses these measures internally for planning, forecasting and evaluating the performance of the Company's segments, including allocating resources. Dow's management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year-over-year results. These non-GAAP measures supplement the Company's GAAP disclosures and should not be viewed as alternatives to GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Non-GAAP measures included in this release are defined below. Reconciliations for these non-GAAP measures to GAAP are provided in the Selected Financial Information and Non-GAAP Measures section starting on page 10. Dow does not provide forward-looking GAAP financial measures or a reconciliation of forward-looking non-GAAP financial measures to the most comparable GAAP financial measures on a forward-looking basis because the Company is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, foreign currency exchange gains or losses and potential future asset impairments, as well as discrete taxable events, without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP results for the guidance period.

Operating Earnings Per Share is defined as "Earnings (loss) per common share - diluted" excluding the after-tax impact of significant items.

Operating EBIT is defined as earnings (i.e., "Income (loss) before income taxes") before interest, excluding the impact of significant items.

Operating EBIT Margin is defined as Operating EBIT as a percentage of net sales.

Operating EBITDA is defined as earnings (i.e., "Income (loss) before income taxes") before interest, depreciation and amortization, excluding the impact of significant items.

Free Cash Flow is defined as "Cash provided by (used for) operating activities - continuing operations," less capital expenditures. Under this definition, Free Cash Flow represents the cash generated by the Company from operations after investing in its asset base. Free Cash Flow, combined with cash balances and other sources of liquidity, represent the cash available to fund obligations and provide returns to shareholders. Free Cash Flow is an integral financial measure used in the Company's financial planning process.

Cash Flow Conversion is defined as "Cash provided by (used for) operating activities - continuing operations," divided by Operating EBITDA. Management believes Cash Flow Conversion is an important financial metric as it helps the Company determine how efficiently it is converting its earnings into cash flow.

Operating Return on Capital (ROC) is defined as net operating profit after tax, excluding the impact of significant items, divided by total average capital, also referred to as ROIC.

Dow Inc. and Subsidiaries

Consolidated Statements of Income

In millions, except per share amounts (Unaudited)

Three Months Ended

Six Months Ended

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Net sales

$   12,092

$   10,104

$   21,886

$   20,535

Cost of sales

9,925

9,521

19,079

19,281

Research and development expenses

207

188

388

388

Selling, general and administrative expenses

535

347

952

713

Amortization of intangibles

40

63

86

139

Restructuring and asset related charges - net

503

591

530

799

Equity in earnings (losses) of nonconsolidated affiliates

36

(30)

(267)

(50)

Sundry income (expense) - net

125

147

246

160

Interest income

38

39

80

67

Interest expense and amortization of debt discount

210

209

429

425

Income (loss) before income taxes

871

(659)

481

(1,033)

Provision for income taxes

69

142

124

58

Net income (loss)

802

(801)

357

(1,091)

Net income attributable to noncontrolling interests

81

34

169

51

Net income (loss) available for Dow Inc. common stockholders

$       721

$      (835)

$       188

$   (1,142)

Per common share data:

Earnings (loss) per common share - basic

$      0.99

$     (1.18)

$      0.25

$     (1.62)

Earnings (loss) per common share - diluted

$      0.99

$     (1.18)

$      0.25

$     (1.62)

Weighted-average common shares outstanding - basic

723.5

709.5

722.4

708.2

Weighted-average common shares outstanding - diluted

725.1

709.5

723.5

708.2

Dow Inc. and Subsidiaries

Consolidated Balance Sheets

In millions, except share amounts (Unaudited)

Jun 30,
2026

Dec 31,
2025

Assets

Current Assets

Cash and cash equivalents (variable interest entities restricted - 2026: $237; 2025: $31)

$         3,973

$         3,816

Accounts and notes receivable:

Trade (net of allowance for doubtful receivables - 2026: $70; 2025: $59)

6,430

4,762

Other

2,049

1,876

Inventories

7,233

6,595

Other current assets

1,186

1,013

Total current assets (variable interest entities restricted - 2026: $443; 2025: $228)

20,871

18,062

Investments

Investment in nonconsolidated affiliates

1,121

1,264

Other investments (investments carried at fair value - 2026: $2,379; 2025: $2,212)

3,289

3,017

Noncurrent receivables

563

309

Total investments

4,973

4,590

Property

Property

66,599

65,863

Less: Accumulated depreciation

44,391

43,613

Net property (variable interest entities restricted - 2026: $2,348; 2025: $2,385)

22,208

22,250

Other Assets

Goodwill

7,934

7,978

Other intangible assets (net of accumulated amortization - 2026: $5,821; 2025: $5,727)

1,371

1,486

Operating lease right-of-use assets

1,367

1,356

Deferred income tax assets

1,570

1,511

Deferred charges and other assets

1,291

1,305

Total other assets (variable interest entities restricted - 2026: $213; 2025: $226)

13,533

13,636

Total Assets

$       61,585

$       58,538

Liabilities and Equity

Current Liabilities

Notes payable

$             86

$             90

Long-term debt due within one year

758

222

Accounts payable:

Trade

5,385

4,151

Other

1,622

1,394

Operating lease liabilities - current

341

340

Income taxes payable

359

337

Accrued and other current liabilities

3,380

2,649

Total current liabilities (variable interest entities nonrecourse - 2026: $461; 2025: $438)

11,931

9,183

Long-Term Debt (variable interest entities nonrecourse - 2026: $179; 2025: $190)

17,151

17,849

Other Noncurrent Liabilities

Deferred income tax liabilities

353

364

Pension and other postretirement benefits - noncurrent

4,462

4,694

Asbestos-related liabilities - noncurrent

582

628

Operating lease liabilities - noncurrent

1,092

1,097

Other noncurrent obligations

8,647

7,201

Total other noncurrent liabilities (variable interest entities nonrecourse - 2026: $339; 2025: $364)

15,136

13,984

Stockholders' Equity

Common stock (authorized 5,000,000,000 shares of $0.01 par value each;

issued 2026: 791,918,759 shares; 2025: 790,287,565 shares)

8

8

Additional paid-in capital

11,073

11,112

Retained earnings

16,457

16,781

Accumulated other comprehensive loss

(7,662)

(7,660)

Treasury stock at cost (2026: 69,578,048 shares; 2025: 73,065,152 shares)

(4,016)

(4,233)

Dow Inc.'s stockholders' equity

15,860

16,008

Noncontrolling interests

1,507

1,514

Total equity

17,367

17,522

Total Liabilities and Equity

$       61,585

$       58,538

Dow Inc. and Subsidiaries

Consolidated Statements of Cash Flows

In millions (Unaudited)

Six Months Ended

Jun 30,
2026

Jun 30,
2025

Operating Activities

Net income (loss)

$          357

$     (1,091)

Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:

Depreciation and amortization

1,383

1,438

Credit for deferred income tax

(114)

(131)

Earnings of nonconsolidated affiliates less than dividends received

543

220

Net periodic pension benefit credit

(16)

(50)

Pension contributions

(78)

(76)

Net gain on sales of assets, businesses and investments

(49)

(102)

Restructuring and asset related charges - net

530

799

Other net loss

3

104

Changes in assets and liabilities, net of effects of acquired and divested companies:

Accounts and notes receivable

(1,761)

(935)

Inventories

(638)

(158)

Accounts payable

1,347

(12)

Other assets and liabilities, net

941

(372)

Cash provided by (used for) operating activities - continuing operations

2,448

(366)

Cash provided by (used for) operating activities - discontinued operations

7

(13)

Cash provided by (used for) operating activities

2,455

(379)

Investing Activities

Capital expenditures

(1,135)

(1,347)

Proceeds from incentives related to capital expenditures

49

—

Cash flow hedging related to capital expenditures

(6)

—

Investment in gas field developments

(48)

(68)

Proceeds from sales of property, businesses and consolidated companies, net of cash divested

58

131

Investments in and loans to nonconsolidated affiliates

(133)

(20)

Purchases of investments

(782)

(205)

Proceeds from sales and maturities of investments

524

552

Other investing activities, net

53

(5)

Cash used for investing activities

(1,420)

(962)

Financing Activities

Changes in short-term notes payable

17

48

Proceeds from issuance of short-term debt greater than three months

16

37

Payments on short-term debt greater than three months

(34)

(41)

Proceeds from issuance of long-term debt

81

1,107

Payments on long-term debt

(206)

(1,114)

Collections on securitization programs, net of remittances

—

18

Transaction financing, debt issuance and other costs

(3)

(85)

Employee taxes paid for share-based payment arrangements

(15)

(16)

Distributions to noncontrolling interests

(158)

(56)

Proceeds from sale of noncontrolling interests

—

2,433

Dividends paid to stockholders

(505)

(990)

Cash provided by (used for) financing activities

(807)

1,341

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(76)

253

Summary

Increase in cash, cash equivalents and restricted cash

152

253

Cash, cash equivalents and restricted cash at beginning of period

3,952

2,263

Cash, cash equivalents and restricted cash at end of period

$       4,104

$       2,516

Less: Restricted cash and cash equivalents, included in "Other current assets"

131

117

Cash and cash equivalents at end of period

$       3,973

$       2,399

Dow Inc. and Subsidiaries

Net Sales by Segment and Geographic Region

Net Sales by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Packaging & Specialty Plastics

$    6,385

$    5,025

$   11,304

$   10,335

Industrial Intermediates & Infrastructure

3,166

2,786

5,792

5,641

Performance Materials & Coatings

2,361

2,129

4,441

4,200

Corporate

180

164

349

359

Total

$   12,092

$   10,104

$   21,886

$   20,535

U.S. & Canada

$     4,782

$     3,988

$     8,578

$     8,215

EMEAI 1

3,930

3,272

7,114

6,546

Asia Pacific

1,817

1,737

3,555

3,595

Latin America

1,563

1,107

2,639

2,179

Total

$   12,092

$   10,104

$   21,886

$   20,535

Net Sales Variance by Segment and
Geographic Region

Three Months Ended Jun 30, 2026

Six Months Ended Jun 30, 2026

Local
Price &
Product
Mix

Currency

Volume

Total

Local
Price &
Product
Mix

Currency

Volume

Total

Percent change from prior year

Packaging & Specialty Plastics

30 %

1 %

(4) %

27 %

10 %

2 %

(3) %

9 %

Industrial Intermediates & Infrastructure

15

1

(2)

14

3

3

(3)

3

Performance Materials & Coatings

4

1

6

11

—

2

4

6

Total

20 %

1 %

(1) %

20 %

6 %

2 %

(1) %

7 %

Total, excluding the Hydrocarbons & Energy
  business

18 %

1 %

— %

19 %

6 %

2 %

— %

8 %

U.S. & Canada

17 %

— %

3 %

20 %

5 %

— %

(1) %

4 %

EMEAI 1

21

3

(4)

20

7

6

(4)

9

Asia Pacific

14

—

(9)

5

3

1

(5)

(1)

Latin America

32

—

9

41

12

—

9

21

Total

20 %

1 %

(1) %

20 %

6 %

2 %

(1) %

7 %

Europe, Middle East, Africa and India. Dow Inc. and Subsidiaries

Selected Financial Information and Non-GAAP Measures

Operating EBIT by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Packaging & Specialty Plastics

$    1,278

$         71

$    1,486

$       413

Industrial Intermediates & Infrastructure

246

(185)

128

(313)

Performance Materials & Coatings

133

152

250

201

Corporate

(9)

(59)

(62)

(92)

Total

$    1,648

$        (21)

$    1,802

$       209

Depreciation and Amortization by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Packaging & Specialty Plastics

$       361

$       369

$       743

$       729

Industrial Intermediates & Infrastructure

137

153

285

299

Performance Materials & Coatings

158

192

339

392

Corporate

8

10

16

18

Total

$       664

$       724

$    1,383

$    1,438

Operating EBITDA by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Packaging & Specialty Plastics

$    1,639

$       440

$    2,229

$    1,142

Industrial Intermediates & Infrastructure

383

(32)

413

(14)

Performance Materials & Coatings

291

344

589

593

Corporate

(1)

(49)

(46)

(74)

Total

$    2,312

$       703

$    3,185

$    1,647

Equity in Earnings (Losses) of Nonconsolidated
Affiliates by Segment

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Packaging & Specialty Plastics 1

$         19

$           7

$        (44)

$         46

Industrial Intermediates & Infrastructure 1

15

(39)

(227)

(97)

Performance Materials & Coatings

1

1

2

1

Corporate

1

1

2

—

Total

$         36

$        (30)

$      (267)

$        (50)

Reconciliation of "Net income (loss)" to "Operating EBIT"

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Net income (loss)

$       802

$      (801)

$       357

$   (1,091)

+ Provision for income taxes

69

142

124

58

Income (loss) before income taxes

$       871

$      (659)

$       481

$   (1,033)

-  Interest income

38

39

80

67

+ Interest expense and amortization of debt discount

210

209

429

425

-  Significant items

(605)

(468)

(972)

(884)

Operating EBIT (non-GAAP)

$    1,648

$        (21)

$    1,802

$       209

Packaging & Specialty Plastics and Industrial Intermediates & Infrastructure include losses of $81 million and $211 million, respectively, in the six months ended June 30, 2026, related to the Sadara guarantee liability adjustment, a significant item. Dow Inc. and Subsidiaries

Selected Financial Information and Non-GAAP Measures

Significant Items Impacting Results for the Three Months Ended Jun 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net 
income
(loss) 2

EPS 3

Income Statement Classification

Reported results

$     871

$     721

$     0.99

Less: Significant items

Transform to Outperform 4

(526)

(418)

(0.58)

SG&A ($81 million); Restructuring and
  asset related charges - net
  ($445 million)

2025 Restructuring Program asset
  related charges and exit and disposal
  costs 5

(58)

(46)

(0.06)

Restructuring and asset related charges
  - net

2025 Restructuring implementation
  costs 6

(28)

(23)

(0.03)

Cost of sales ($27 million); 
  R&D ($1 million)

Indemnification and other transaction
  related credits 7

7

7

0.01

Sundry income (expense) - net

Income tax related items 8

—

150

0.21

Provision for income taxes

  Total significant items

$    (605)

$    (330)

$   (0.45)

Operating results (non-GAAP)

$   1,476

$   1,051

$     1.44

Significant Items Impacting Results for the Three Months Ended Jun 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net 
income
(loss) 2

EPS 3

Income Statement Classification

Reported results

$    (659)

$    (835)

$   (1.18)

Less: Significant items

2025 Restructuring Program severance
  and related benefit costs and asset
  related charges 5

(591)

(474)

(0.67)

Restructuring and asset related charges
  - net

Implementation costs 6

(5)

(4)

(0.01)

Cost of sales ($1 million);

 SG&A ($4 million)

Net gain on divestitures and asset sale 9

103

77

0.11

Sundry income (expense) - net

Litigation related charges, awards and
  adjustments 10

42

33

0.05

Cost of sales

Indemnification and other transaction
  related costs 7

(17)

(17)

(0.02)

Sundry income (expense) - net

Income tax related items 8

—

(153)

(0.22)

Provision for income taxes

  Total significant items

$    (468)

$    (538)

$   (0.76)

Operating results (non-GAAP)

$    (191)

$    (297)

$   (0.42)

"Income (loss) before income taxes." "Net income (loss) available for Dow Inc. common stockholders." The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. "Earnings (loss) per common share - diluted," which includes the impact of participating securities in accordance with the two-class method. Includes costs to achieve of $81 million and severance and related benefit costs of $445 million associated with Transform to Outperform. For 2026, includes impairment charges related to the write-down of certain manufacturing facilities and other miscellaneous assets and exit and disposal costs associated with the Company's 2025 Restructuring program. For 2025, includes severance and related benefit costs and impairment charges related to the write-down of certain manufacturing facilities, corporate assets, leased non-manufacturing facilities and other miscellaneous assets associated with the Company's 2025 Restructuring Program. For 2026, includes implementation costs associated with the Company's 2025 Restructuring Program. For 2025, also includes implementation costs associated with the sale of membership interests of the Company's formerly wholly owned subsidiary, Dow InfraCo, LLC. Relates to credits (charges) associated with agreements entered into with DuPont and Corteva as part of the separation and distribution which, among other matters, provides for cross-indemnities and allocations of obligations and liabilities for periods prior to, at and after the completion of the separation. For 2026, amount relates to changes in the Company's ability to utilize foreign tax credits associated with cash proceeds received in March 2026 related to a legal matter with Nova Chemicals Corporation ("Nova"). For 2025, amounts relate to valuation allowances on deferred tax assets in certain foreign jurisdictions, partially offset by a tax basis adjustment related to the Company's consolidated infrastructure entity. Relates to a gain on the sale of the Company's soil fumigation product line. Includes a gain associated with the reassessment of liabilities for certain accrued legacy agricultural products groundwater contamination matters, partially offset by the settlement of a separate claim related to water storage district legacy groundwater contamination matters. Dow Inc. and Subsidiaries

Selected Financial Information and Non-GAAP Measures

Significant Items Impacting Results for the Six Months Ended Jun 30, 2026

In millions, except per share amounts (Unaudited)

Pretax 1

Net
Income 2

EPS 3

Income Statement Classification

Reported results

$     481

$     188

$     0.25

Less: Significant items

Transform to Outperform 4

(606)

(481)

(0.67)

SG&A ($134 million); Restructuring
  and asset related charges - net
  ($472 million)

2025 Restructuring Program asset
  related charges and exit and disposal
  costs 5

(58)

(46)

(0.06)

Restructuring and asset related charges
  - net

2025 Restructuring implementation
  costs 6

(49)

(40)

(0.05)

Cost of sales ($47 million);
  R&D ($1 million); SG&A ($1 million)

Sadara guarantee liability adjustment 7

(292)

(227)

(0.31)

Equity in losses of nonconsolidated
  affiliates

Litigation related charges, awards and
  adjustments 8

26

21

0.03

Sundry income (expense) - net

Indemnification and other transaction
  related credits 9

7

7

0.01

Sundry income (expense) - net

  Total significant items

$     (972)

$    (766)

$    (1.05)

Operating results (non-GAAP)

$   1,453

$     954

$     1.30

"Income (loss) before income taxes." "Net income (loss) available for Dow Inc. common stockholders." The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. "Earnings (loss) per common share - diluted," which includes the impact of participating securities in accordance with the two-class method. Includes costs to achieve of $134 million and severance and related benefit costs of $472 million associated with Transform to Outperform. Includes impairment charges related to the write-down of certain manufacturing facilities and other miscellaneous assets and exit and disposal costs associated with the Company's 2025 Restructuring program. Includes implementation costs associated with the Company's 2025 Restructuring Program. Includes a charge due to a change in fair value of the estimated liability associated with the Company's guarantee of Sadara's project financing debt. Relates to a gain associated with a legal matter with Nova. Relates to credits associated with agreements entered into with DuPont and Corteva as part of the separation and distribution which, among other matters, provides for cross-indemnities and allocations of obligations and liabilities for periods prior to, at and after the completion of the separation. Dow Inc. and Subsidiaries

Selected Financial Information and Non-GAAP Measures

Significant Items Impacting Results for the Six Months Ended Jun 30, 2025

In millions, except per share amounts (Unaudited)

Pretax 1

Net Income 2

EPS 3

Income Statement Classification

Reported results

$ (1,033)

$ (1,142)

$   (1.62)

Less: Significant items

Restructuring, implementation and
  efficiency costs, and asset related
  charges - net 4

(51)

(39)

(0.05)

Cost of sales ($44 million);

R&D ($1 million); SG&A ($4 million);
  Restructuring and asset related
  charges - net ($1 million); Sundry
  income (expense) - net ($1 million)

2025 Restructuring Program severance
  and related benefit costs and asset
  related charges 5

(798)

(635)

(0.90)

Restructuring and asset related charges
- net

Implementation costs 6

(5)

(4)

(0.01)

Cost of sales ($1 million);

 SG&A ($4 million)

Net gain on divestitures and asset sale 7

103

77

0.11

Sundry income (expense) - net

Litigation related charges, awards and
  adjustments 8

42

33

0.05

Cost of sales

Loss on early extinguishment of debt

(60)

(48)

(0.07)

Sundry income (expense) - net

Indemnification and other transaction
  related costs 9

(115)

(93)

(0.13)

Cost of sales ($98 million); Sundry
  income (expense) - net ($17 million)

Income tax related items 10

—

(153)

(0.22)

Provision for income taxes

  Total significant items

$    (884)

$    (862)

$   (1.22)

Operating results (non-GAAP)

$    (149)

$    (280)

$   (0.40)

"Income (loss) before income taxes." "Net income (loss) available for Dow Inc. common stockholders." The income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment. "Earnings (loss) per common share - diluted," which includes the impact of participating securities in accordance with the two-class method. Includes restructuring charges and implementation and efficiency costs associated with the Company's 2023 Restructuring program. Includes severance and related benefit costs and impairment charges related to the write-down of certain manufacturing facilities, corporate assets, leased non-manufacturing facilities and other miscellaneous assets associated with the Company's 2025 Restructuring program. Includes implementation costs associated with the Company's 2025 Restructuring Program and the sale of membership interests of the Company's formerly wholly owned subsidiary, Dow InfraCo, LLC. Relates to a gain on the sale of the Company's soil fumigation product line. Includes a gain associated with the reassessment of liabilities for certain accrued legacy agricultural products groundwater contamination matters, partially offset by the settlement of a separate claim related to water storage district legacy groundwater contamination matters. Primarily includes a charge related to an arbitration settlement agreement for historical product claims from a divested business. Also includes charges associated with agreements entered into with DuPont and Corteva as part of the separation and distribution which, among other matters, provides for cross-indemnities and allocations of obligations and liabilities for periods prior to, at and after the completion of the separation. Relates to valuation allowances on deferred tax assets in certain foreign jurisdictions, partially offset by a tax basis adjustment related to the Company's consolidated infrastructure entity. Dow Inc. and Subsidiaries

Selected Financial Information and Non-GAAP Measures

Reconciliation of Free Cash Flow

Three Months Ended

Six Months Ended

In millions (Unaudited)

Jun 30,
2026

Jun 30,
2025

Jun 30,
2026

Jun 30,
2025

Cash provided by (used for) operating activities - continuing
  operations (GAAP)

$     1,324

$       (470)

$    2,448

$      (366)

Capital expenditures

(632)

(662)

(1,135)

(1,347)

Free Cash Flow (non-GAAP)

$        692

$    (1,132)

$    1,313

$   (1,713)

Reconciliation of Cash Flow Conversion

Three Months Ended

In millions (Unaudited)

Sep 30,
2025

Dec 31,
2025

Mar 31,
2026

Jun 30,
2026

Cash provided by operating activities - continuing operations
  (GAAP)

$  1,130

$     298

$  1,124

$  1,324

Net income (loss) (GAAP)

$     124

$ (1,477)

$    (445)

$     802

Cash flow from operations to net income (GAAP) 1

911.3 %

N/A

N/A

165.1 %

Cash flow from operations to net income - trailing twelve months
(GAAP) 2

N/A

Operating EBITDA (non-GAAP)

$     868

$     741

$     873

$  2,312

Cash Flow Conversion (Cash flow from operations to Operating
  EBITDA) (non-GAAP)

130.2 %

40.2 %

128.8 %

57.3 %

Cash Flow Conversion - trailing twelve months (non-GAAP)

80.9 %

Cash flow from operations to net income is not applicable for the fourth quarter of 2025 and first quarter of 2026 due to a net loss for the period. Cash flow from operations to net income - trailing twelve months is not applicable due to a net loss for the trailing twelve months period. SOURCE The Dow Chemical Company

Posted by Defense World Staff on Jul 23rd, 2026

Aureus Asset Management LLC purchased a new position in shares of Wells Fargo & Company (NYSE:WFC – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 21,518 shares of the financial services provider’s stock, valued at approximately $1,713,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Diversified Trust Co. grew its stake in Wells Fargo & Company by 59.7% in the 4th quarter. Diversified Trust Co. now owns 35,285 shares of the financial services provider’s stock valued at $3,289,000 after acquiring an additional 13,196 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Wells Fargo & Company by 19.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 532,300 shares of the financial services provider’s stock valued at $49,610,000 after purchasing an additional 84,902 shares in the last quarter. Swiss Life Asset Management Ltd lifted its holdings in shares of Wells Fargo & Company by 4.2% in the fourth quarter. Swiss Life Asset Management Ltd now owns 350,567 shares of the financial services provider’s stock valued at $32,673,000 after purchasing an additional 14,168 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of Wells Fargo & Company by 4.4% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 412,511 shares of the financial services provider’s stock valued at $38,446,000 after purchasing an additional 17,302 shares during the last quarter. Finally, Winning Points Advisors LLC purchased a new position in shares of Wells Fargo & Company during the 4th quarter worth approximately $3,384,000. Hedge funds and other institutional investors own 75.90% of the company’s stock.

More Wells Fargo & Company News Here are the key news stories impacting Wells Fargo & Company this week:

Positive Sentiment: Wells Fargo reported Q2 2026 earnings with EPS up 25%, supported by revenue growth and efficiency gains across all segments, reinforcing the company’s operating momentum. Wells Fargo Q2 2026 Earnings Call Transcript Positive Sentiment: The bank raised its dividend by 11% to $0.50 per share after passing the Federal Reserve stress test with a CET1 ratio comfortably above required levels, which signals balance-sheet strength and capital flexibility. This High-Yield Bank Stock Just Raised Its Dividend by 11% Positive Sentiment: Wall Street analysts remain broadly constructive on WFC, and recent coverage highlights that broker recommendations continue to lean bullish on the stock. Wall Street Bulls Look Optimistic About Wells Fargo (WFC): Should You Buy? Positive Sentiment: Wells Fargo also appointed Tom Nicholls to lead Sports Investment Banking, a move that suggests it is expanding higher-fee advisory capabilities in a niche growth area. Wells Fargo (WFC) Appoints Tom Nicholls To Lead Sports Investment Banking Neutral Sentiment: WFC is also showing up on “trending stocks” lists, reflecting elevated investor interest rather than a clear fundamental catalyst by itself. Wells Fargo & Company (WFC) Is a Trending Stock: Facts to Know Before Betting on It Neutral Sentiment: Broader market commentary favoring banks over volatile tech names is also providing a supportive backdrop for large financials like Wells Fargo. This High-Yield Bank Stock Just Raised Its Dividend by 11% Negative Sentiment: A MarketWatch piece about a customer receiving a lower-than-expected credit limit on a balance-transfer request could add to scrutiny around Wells Fargo’s consumer lending practices, though it appears anecdotal rather than company-wide. I wanted to transfer $17,000 in credit-card debt. Why did Wells Fargo offer me only a $4,000 credit limit? Wall Street Analysts Forecast Growth A number of equities research analysts recently issued reports on the company. Bank of America upped their target price on Wells Fargo & Company from $95.00 to $102.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Truist Financial boosted their price target on Wells Fargo & Company from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Robert W. Baird upped their price objective on Wells Fargo & Company from $85.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price objective (down from $100.00) on shares of Wells Fargo & Company in a research note on Wednesday, April 15th. Finally, HSBC raised shares of Wells Fargo & Company from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research note on Wednesday, April 1st. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.50.

Get Our Latest Analysis on WFC

Wells Fargo & Company Trading Down 1.3% Shares of Wells Fargo & Company stock opened at $86.61 on Thursday. Wells Fargo & Company has a fifty-two week low of $72.78 and a fifty-two week high of $97.76. The firm has a market cap of $265.05 billion, a PE ratio of 12.59, a P/E/G ratio of 0.96 and a beta of 0.92. The business’s fifty day moving average is $82.21 and its two-hundred day moving average is $83.55. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.09.

Wells Fargo & Company Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 8th were paid a dividend of $0.45 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.1%. Wells Fargo & Company’s dividend payout ratio is currently 26.16%.

About Wells Fargo & Company (Free Report)

Wells Fargo & Company is a diversified, U.S.-based financial services company headquartered in San Francisco, California. Founded in 1852 by Henry Wells and William G. Fargo, the firm has evolved from its origins in express delivery and pioneer-era banking into one of the largest full-service banks in the United States. The company provides a broad range of financial products and services to individual, small business, commercial, and institutional clients. Charles W. Scharf serves as chief executive officer.

Wells Fargo operates across several core business segments, including consumer banking and lending, commercial banking, corporate and investment banking, and wealth and investment management.

Read More Five stocks we like better than Wells Fargo & Company Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Wells Fargo & Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wells Fargo & Company and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEABN Amro Investment Solutions Sells 24,787 Shares of Blackstone Inc. $BX

NEXT HEADLINE »ABN Amro Investment Solutions Boosts Position in T-Mobile US, Inc. $TMUS

Posted by Defense World Staff on Jul 23rd, 2026

ABN Amro Investment Solutions lessened its stake in shares of U.S. Bancorp (NYSE:USB – Free Report) by 32.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,205 shares of the financial services provider’s stock after selling 81,756 shares during the period. ABN Amro Investment Solutions’ holdings in U.S. Bancorp were worth $8,904,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Paulson Wealth Management Inc. raised its holdings in U.S. Bancorp by 2.0% in the fourth quarter. Paulson Wealth Management Inc. now owns 8,780 shares of the financial services provider’s stock worth $469,000 after buying an additional 173 shares during the last quarter. Flputnam Investment Management Co. grew its holdings in shares of U.S. Bancorp by 1.4% during the fourth quarter. Flputnam Investment Management Co. now owns 13,721 shares of the financial services provider’s stock valued at $732,000 after buying an additional 186 shares during the last quarter. Formidable Asset Management LLC grew its holdings in shares of U.S. Bancorp by 0.8% during the first quarter. Formidable Asset Management LLC now owns 23,373 shares of the financial services provider’s stock valued at $1,247,000 after buying an additional 186 shares during the last quarter. Balboa Wealth Partners increased its position in shares of U.S. Bancorp by 4.0% during the first quarter. Balboa Wealth Partners now owns 4,920 shares of the financial services provider’s stock valued at $256,000 after acquiring an additional 188 shares in the last quarter. Finally, Richmond Investment Services LLC increased its position in shares of U.S. Bancorp by 1.9% during the fourth quarter. Richmond Investment Services LLC now owns 10,107 shares of the financial services provider’s stock valued at $539,000 after acquiring an additional 192 shares in the last quarter. 77.60% of the stock is owned by institutional investors.

U.S. Bancorp Trading Up 1.2% NYSE:USB opened at $64.48 on Thursday. The company has a current ratio of 0.83, a quick ratio of 0.82 and a debt-to-equity ratio of 0.96. U.S. Bancorp has a 12 month low of $43.46 and a 12 month high of $64.84. The company has a market cap of $100.02 billion, a PE ratio of 12.87, a price-to-earnings-growth ratio of 1.04 and a beta of 0.96. The company has a 50 day simple moving average of $58.48 and a two-hundred day simple moving average of $56.30.

U.S. Bancorp (NYSE:USB – Get Free Report) last announced its earnings results on Thursday, July 16th. The financial services provider reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.07. The business had revenue of $7.71 billion during the quarter, compared to analyst estimates of $7.58 billion. U.S. Bancorp had a net margin of 18.49% and a return on equity of 13.69%. During the same period in the previous year, the business earned $1.11 EPS. Research analysts forecast that U.S. Bancorp will post 5.22 earnings per share for the current year.

U.S. Bancorp Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Wednesday, July 15th. Investors of record on Tuesday, June 30th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Tuesday, June 30th. U.S. Bancorp’s dividend payout ratio is 41.52%.

Insiders Place Their Bets In other U.S. Bancorp news, EVP Venkatachari Dilip sold 34,522 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $55.52, for a total value of $1,916,661.44. Following the transaction, the executive vice president directly owned 51,292 shares of the company’s stock, valued at approximately $2,847,731.84. This trade represents a 40.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.21% of the company’s stock.

Analyst Upgrades and Downgrades Several analysts have commented on USB shares. Raymond James Financial began coverage on U.S. Bancorp in a research note on Wednesday, July 8th. They set a “strong-buy” rating and a $72.00 target price on the stock. Stephens boosted their price target on U.S. Bancorp from $63.00 to $67.00 and gave the stock an “equal weight” rating in a research note on Friday, July 17th. Wells Fargo & Company increased their price objective on U.S. Bancorp from $66.00 to $69.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. JPMorgan Chase & Co. upgraded U.S. Bancorp from an “underweight” rating to a “neutral” rating and lifted their price objective for the stock from $65.00 to $67.50 in a report on Monday. Finally, Evercore raised U.S. Bancorp from an “in-line” rating to an “outperform” rating and set a $72.00 target price for the company in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $67.00.

View Our Latest Analysis on U.S. Bancorp

U.S. Bancorp Profile (Free Report)

U.S. Bancorp (NYSE: USB) is a bank holding company and the parent of U.S. Bank, a national commercial bank that provides a wide range of banking, investment, mortgage, trust and payment services. The company operates through consumer and business banking, commercial banking, payment services, and wealth management segments. Its product set includes deposit accounts, consumer and commercial lending, mortgage origination and servicing, credit and debit card services, treasury and cash management, merchant processing, and institutional and trust services.

Headquartered in Minneapolis, Minnesota, U.S.

Read More Five stocks we like better than U.S. Bancorp Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding USB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for U.S. Bancorp (NYSE:USB – Free Report).

Receive News & Ratings for U.S. Bancorp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Bancorp and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINENVIDIA Corporation $NVDA Holdings Lifted by 180 Wealth Advisors LLC

NEXT HEADLINE »Alamar Capital Management LLC Purchases Shares of 8,480 Oracle Corporation $ORCL

Posted by Defense World Staff on Jul 23rd, 2026

California Public Employees Retirement System reduced its stake in First Solar, Inc. (NASDAQ:FSLR – Free Report) by 26.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 128,905 shares of the solar cell manufacturer’s stock after selling 46,070 shares during the quarter. California Public Employees Retirement System owned approximately 0.12% of First Solar worth $25,428,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Reflection Asset Management acquired a new position in First Solar in the 4th quarter valued at about $26,000. Commonwealth Retirement Investments LLC acquired a new stake in shares of First Solar during the 4th quarter worth approximately $26,000. Larson Financial Group LLC raised its position in shares of First Solar by 117.0% during the 4th quarter. Larson Financial Group LLC now owns 102 shares of the solar cell manufacturer’s stock valued at $27,000 after buying an additional 55 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of First Solar during the 4th quarter valued at approximately $30,000. Finally, MV Capital Management Inc. acquired a new position in First Solar in the fourth quarter valued at approximately $30,000. 92.08% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at First Solar In other First Solar news, CFO Alexander R. Bradley sold 498 shares of the stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $215.63, for a total value of $107,383.74. Following the sale, the chief financial officer owned 30,712 shares of the company’s stock, valued at $6,622,428.56. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Georges Antoun sold 566 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $215.63, for a total value of $122,046.58. Following the transaction, the insider directly owned 19,918 shares of the company’s stock, valued at approximately $4,294,918.34. This represents a 2.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 31,893 shares of company stock valued at $7,893,775 in the last 90 days. Insiders own 0.39% of the company’s stock.

Trending Headlines about First Solar Here are the key news stories impacting First Solar this week:

Positive Sentiment: TD Cowen was reported to have a Buy view on First Solar, which may have supported bullish sentiment around the stock. Article Title Positive Sentiment: First Solar was highlighted as rising while the broader market dipped, suggesting relative strength and investor demand for the solar name. Article Title Neutral Sentiment: Analyst commentary across the sector was described as mixed, which adds some uncertainty but does not appear to have changed the core investment case by itself. Article Title Negative Sentiment: Multiple law firms are promoting a securities class action tied to First Solar, with lead-plaintiff deadlines and allegations of investor losses, which can weigh on sentiment and raise legal overhang concerns. Article Title Negative Sentiment: The newly filed class action and related shareholder notices add legal risk and could pressure the stock if investors focus on potential damages and management scrutiny. Article Title Wall Street Analyst Weigh In Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised First Solar from a “hold” rating to a “buy” rating and raised their target price for the stock from $245.00 to $272.00 in a research note on Monday, July 6th. TD Cowen reiterated a “buy” rating on shares of First Solar in a report on Monday. Zacks Research raised First Solar from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Wells Fargo & Company boosted their price objective on shares of First Solar from $255.00 to $320.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $207.00 target price on shares of First Solar in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, First Solar has a consensus rating of “Moderate Buy” and a consensus target price of $257.10.

Check Out Our Latest Stock Report on First Solar

First Solar Stock Performance NASDAQ FSLR opened at $208.86 on Thursday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.56 and a quick ratio of 2.15. The company has a market cap of $22.44 billion, a P/E ratio of 13.49, a P/E/G ratio of 0.46 and a beta of 1.73. The stock has a 50-day moving average of $249.71 and a two-hundred day moving average of $227.57. First Solar, Inc. has a 1-year low of $171.99 and a 1-year high of $320.95.

First Solar (NASDAQ:FSLR – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The solar cell manufacturer reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.87 by $0.35. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.03 billion. First Solar had a net margin of 30.73% and a return on equity of 18.01%. The business’s quarterly revenue was up 23.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.95 earnings per share. As a group, analysts anticipate that First Solar, Inc. will post 17.54 EPS for the current year.

First Solar Company Profile (Free Report)

First Solar, Inc (NASDAQ: FSLR) is a United States–based solar technology company best known for designing and manufacturing thin‑film photovoltaic (PV) modules that use cadmium telluride (CdTe) semiconductor technology. The company supplies PV modules and delivers integrated solar power solutions for utility‑scale projects, positioning itself as a provider of both components and complete solar energy systems rather than solely a parts supplier. First Solar was founded in 1999 and is headquartered in Tempe, Arizona.

Beyond module manufacturing, First Solar offers a range of project services including development support, engineering, procurement and construction (EPC) services, and operations and maintenance (O&M) for large-scale solar installations.

Read More Five stocks we like better than First Solar Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for First Solar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Solar and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBank of New York Mellon Corp Has $63.15 Million Stock Holdings in Lincoln National Corporation $LNC

NEXT HEADLINE »California Public Employees Retirement System Sells 260,331 Shares of Hasbro, Inc. $HAS

Posted by Defense World Staff on Jul 23rd, 2026

AR Asset Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 5.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 45,226 shares of the company’s stock after purchasing an additional 2,266 shares during the period. AbbVie accounts for about 1.9% of AR Asset Management Inc.’s portfolio, making the stock its 14th largest position. AR Asset Management Inc.’s holdings in AbbVie were worth $9,836,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ABBV. NewEdge Wealth LLC lifted its stake in shares of AbbVie by 2.1% during the 1st quarter. NewEdge Wealth LLC now owns 406,062 shares of the company’s stock worth $88,314,000 after purchasing an additional 8,385 shares during the last quarter. Wiregrass Investment Management LLC grew its stake in AbbVie by 73.6% in the first quarter. Wiregrass Investment Management LLC now owns 5,094 shares of the company’s stock valued at $1,108,000 after purchasing an additional 2,159 shares during the last quarter. First Citizens Bank & Trust Co. boosted its holdings in shares of AbbVie by 24.6% in the 1st quarter. First Citizens Bank & Trust Co. now owns 42,327 shares of the company’s stock valued at $9,206,000 after buying an additional 8,362 shares in the last quarter. Acumen Wealth Advisors LLC boosted its holdings in shares of AbbVie by 270.3% in the 1st quarter. Acumen Wealth Advisors LLC now owns 4,221 shares of the company’s stock valued at $918,000 after buying an additional 3,081 shares in the last quarter. Finally, First Trust Advisors LP grew its position in shares of AbbVie by 13.7% in the 1st quarter. First Trust Advisors LP now owns 1,519,986 shares of the company’s stock worth $330,582,000 after buying an additional 183,488 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance Shares of ABBV stock opened at $253.75 on Thursday. The business has a fifty day moving average of $232.69 and a 200 day moving average of $222.41. AbbVie Inc. has a 1 year low of $186.77 and a 1 year high of $261.64. The firm has a market capitalization of $448.32 billion, a price-to-earnings ratio of 125.00, a price-to-earnings-growth ratio of 0.85 and a beta of 0.30.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. As a group, equities research analysts expect that AbbVie Inc. will post 14.18 earnings per share for the current year.

AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 340.89%.

Wall Street Analyst Weigh In ABBV has been the subject of a number of analyst reports. Cantor Fitzgerald increased their target price on shares of AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, July 6th. Guggenheim lifted their price target on shares of AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. Wells Fargo & Company increased their price target on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, July 10th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $268.10.

Check Out Our Latest Research Report on AbbVie

AbbVie News Roundup Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Canaccord Genuity raised its price target on AbbVie to $282 from $273 and reiterated a buy rating, signaling confidence in further upside for AbbVie Inc. (ABBV). Benzinga report Positive Sentiment: AbbVie’s aesthetics business got a boost after Allergan Aesthetics received European Commission approval for Boey, expanding the company’s portfolio in Europe and potentially supporting future revenue growth. Yahoo Finance article Neutral Sentiment: Several recent articles characterized AbbVie as a strong buy-and-hold name and noted that the stock has recently outperformed the broader market, reinforcing a generally constructive long-term view. Yahoo Finance article Negative Sentiment: Investors are watching AbbVie’s Q2 oncology revenue closely, with analysts warning that weakness in Imbruvica may outweigh gains from Venclexta and newer cancer treatments, which could pressure results. Yahoo Finance article AbbVie Profile (Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.

Featured Articles Five stocks we like better than AbbVie Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESprouts Farmers Market, Inc. $SFM Shares Sold by ABN Amro Investment Solutions

NEXT HEADLINE »Johnson & Johnson $JNJ Shares Acquired by AR Asset Management Inc.

Nathan Blecharczyk, Chief Strategy Officer at Airbnb, Inc. (ABNB -2.81%), disposed of 17,692 shares of Class A Common Stock on July 20, 2026, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value$2.6 millionShares sold13,615Shares gifted4,077Post-transaction shares (total)94,001Post-transaction shares (directly held)81,631Post-transaction shares (indirectly held)12,370Post-transaction value$13.62 millionTransaction value based on SEC Form 4 weighted average sale price ($145.43); post-transaction value based on July 20, 2026, market close ($144.94).

Key questionsWhat was the technical nature of this disposal?
The transaction involved the exercise of 17,692 options that were immediately converted into shares and disposed of via an indirect trust. This resulted in a 59% reduction in the insider's indirect Class A equity, while his direct stake of 81,631 shares was preserved.What is the insider's remaining beneficial ownership?
Following these transactions, the insider's total beneficial ownership stands at 94,001 Class A shares. However, he remains heavily invested via ~45.7 million indirect derivative securities, including Class B Common Stock, which is convertible into Class A shares on a one-to-one basis.How did the Rule 10b5-1 plan influence the timing?
The sales and gifts were pre-arranged under a trading plan adopted on Aug. 28, 2025. Such plans allow insiders to diversify their portfolios on a schedule set months in advance, minimizing the discretionary timing of transactions relative to current market volatility.What was the stock's performance context on the date of the trade?
As of July 20, 2026, the stock had a one-year return of 4%. The weighted average execution price of $145.43 per share was slightly higher than the market close of $144.94 on the same day.Company OverviewMetricValueShare Price (as of market close 2026-07-21)$144.10Market Capitalization$83.1 billionRevenue (TTM)$12.6 billionNet Income (TTM)$2.5 billionCompany SnapshotAirbnb operates a global digital marketplace that connects hosts offering accommodations and unique local experiences with guests seeking travel services, generating revenue primarily through booking commissions and service fees on transactions conducted through its online and mobile platforms.The company's business model leverages a two-sided marketplace structure, earning revenue by taking a percentage of each booking transaction while maintaining minimal capital expenditure through its asset-light approach to accommodation provision.Airbnb's primary customers include leisure and business travelers worldwide seeking alternative accommodations, as well as property owners and hosts looking to monetize their residential spaces and generate supplementary income.Airbnb is a leading global digital marketplace for short-term lodging and experiential travel services, with a market capitalization of $83.1 billion and TTM revenue of $12.6 billion. The company's competitive advantage derives from its extensive network of hosts, diverse inventory spanning multiple accommodation types, and integrated platform technology that facilitates seamless cross-border transactions. With 8,200 employees and operations spanning numerous international markets, Airbnb has established itself as a transformative force in the travel and hospitality sector through its innovative marketplace model.

What this transaction means for investorsI don’t believe this transaction is anything for Airbnb shareholders to worry about. The sales and gifts are part of a trading strategy set up last year and don’t really indicate any timing around the company’s share price or operational performance.

Investors are better off focusing on Airbnb’s actual operations, which appear to be in the midst of a solid turnaround, despite the stock’s price largely being flat over the last few years. The company just grew sales by 18% in its last quarter and is guiding for low-to-mid-teens growth for the full year. Most importantly, in my opinion, Airbnb’s diversification into experiences appears to be gaining traction.

Management explained that “almost a quarter of new guests who book an Experience go on to book a stay or a service, and about one in three people who book an Experience book a stay within 90 days.” Trading at 28 times forward earnings, Airbnb’s double-digit growth and experiences potential could be reasonably priced.

Personally, I still hold shares of Airbnb but have paused adding to them, as I’d like to see sales growth reaccelerate or stock-based compensation reined in a bit more.

CORTE MADERA, Calif.--(BUSINESS WIRE)--RH (NYSE: RH) announced today the promotion of Sandy Pilon to Chief Customer Experience & Values Officer. In her new role, Sandy will lead the Company's Gallery, Hospitality, Interior Design, Trade, Contract, Delight, People and Optimization teams across every touchpoint of the RH Brand globally. Sandy has been a member of Team RH for 18 years and has held key leadership positions across the organization, including Field Leader of our Northern and Sout.

Posted by Defense World Staff on Jul 23rd, 2026

ABN Amro Investment Solutions boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 14.0% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 112,131 shares of the biopharmaceutical company’s stock after acquiring an additional 13,812 shares during the quarter. ABN Amro Investment Solutions’ holdings in Bristol Myers Squibb were worth $6,801,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Bristol Myers Squibb by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after acquiring an additional 2,743,759 shares during the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the last quarter. Geode Capital Management LLC lifted its position in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after purchasing an additional 6,084,046 shares during the period. Norges Bank acquired a new position in Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. Finally, AQR Capital Management LLC boosted its holdings in Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock valued at $1,391,485,000 after purchasing an additional 16,332,924 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Down 0.2% NYSE BMY opened at $60.79 on Thursday. The business has a fifty day moving average price of $57.29 and a 200 day moving average price of $57.94. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a market cap of $124.14 billion, a P/E ratio of 17.08, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the business posted $1.80 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Analyst Ratings Changes A number of research firms have weighed in on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, April 8th. UBS Group reaffirmed a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a report on Monday, July 6th. Finally, Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $61.25.

Get Our Latest Stock Analysis on Bristol Myers Squibb

Bristol Myers Squibb Profile (Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Further Reading Five stocks we like better than Bristol Myers Squibb Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAureus Asset Management LLC Takes Position in Dell Technologies Inc. $DELL

NEXT HEADLINE »Alamar Capital Management LLC Invests $2.10 Million in Tenet Healthcare Corporation $THC

SK Hynix was outdoing its U.S. rival after Alphabet earnings.

An employee of e-commerce MercadoLibre works at the company's offices in Buenos Aires, Argentina September 6, 2024. REUTERS/Agustin Marcarian Purchase Licensing Rights, opens new tab

SANTIAGO, July 23 (Reuters) - E-commerce firm MercadoLibre (MELI.O), opens new tab has discussed a proposal with Chilean authorities to operate as a pharmacy in the country, a plan that would require a change in ​local regulations, records of meetings between the parties showed.

The move would mark the latest step ‌by Uruguay-based MercadoLibre, once primarily a marketplace for external sellers, toward expanding its own retail operations while deepening its push into pharmacies after a similar pilot in Brazil.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

MercadoLibre, which operates across Latin America and is one of the region's largest ​firms by market capitalization, met with Chilean officials at least six times in the past year. ​Meeting minutes revealed MercadoLibre's previously unreported plan to operate an in-house and online-only ⁠pharmacy model in Chile.

The plan would expand the firm's Chile operations, where, as in Argentina, Mexico and other markets, ​MercadoLibre currently only sells medication from third-party retailers.

After hearing the plan, Chile's health ministry recommended that MercadoLibre seek ​a technical evaluation from the nation's Public Health Institute (ISP), since the proposal would require regulatory changes or reinterpretations, according to records from a January meeting.

ISP in a written response to a request for comment did not detail whether MercadoLibre had ​requested that evaluation. It said MercadoLibre currently does not have authorization to operate an in-house drugstore in ​Chile, and that current regulations do not allow for the operation of an online-only drugstore.

Chile's health ministry did not ‌respond to ⁠requests for comment.

MercadoLibre said in a statement to Reuters that it was working to gradually expand its health offering, adapting to each market's regulatory framework. It declined to comment specifically on plans in Chile.

As part of a broader long-term business strategy, the firm has increased investment in its in-house retail operations in ​recent quarters, focusing on segments ​such as beauty and ⁠household appliances.

That strategy has pressured margins, causing the stock to tumble almost 11% so far this year to $1,799 each.

In Brazil, its biggest market, MercadoLibre bought a physical drugstore last year ​due to local rules requiring a brick-and-mortar presence for companies selling medicines. ​It began a ⁠pilot there in March selling over-the-counter medicines, promising delivery in an average of up to three hours. It has yet to expand outside of Sao Paulo.

The firm's pitch in Chile also included deliveries in "a few hours ⁠in some ​regions," according to minutes from a meeting in September.

Chile lags ​behind the company's largest markets of Brazil, Mexico and Argentina, but a successful rollout there could serve as a model for expansion ​across Latin America.

Reporting by Kylie Madry in Santiago and Andre Romani in Sao Paulo; Editing by Mark Porter

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Kylie Madry is a headline news reporter covering business, politics and breaking news for all of Latin America. She's based out of the Reuters office in Mexico City, where she was previously a freelance journalist and translator working on award-winning podcasts, books about Mexico's drug lords and stories ranging from the fight for clean water to the millions spent on the city's surveillance system. Kylie is originally from Dallas, Texas.

NEW YORK--(BUSINESS WIRE)---- $REGN #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. ("“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of the September 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California an.

Posted by Defense World Staff on Jul 23rd, 2026

ABN Amro Investment Solutions increased its stake in Abbott Laboratories (NYSE:ABT – Free Report) by 10.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,222 shares of the healthcare product maker’s stock after purchasing an additional 9,071 shares during the quarter. ABN Amro Investment Solutions’ holdings in Abbott Laboratories were worth $9,468,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. United Bank raised its holdings in Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after purchasing an additional 292,547 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In ABT has been the subject of several research reports. The Goldman Sachs Group cut their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Barclays dropped their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a report on Monday, April 20th. Jefferies Financial Group cut their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Argus lowered their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Get Our Latest Report on Abbott Laboratories

Abbott Laboratories Price Performance NYSE:ABT opened at $100.69 on Thursday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a market cap of $175.38 billion, a price-to-earnings ratio of 32.59, a price-to-earnings-growth ratio of 1.93 and a beta of 0.61. The company’s 50-day moving average is $90.92 and its two-hundred day moving average is $101.48. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT – Get Free Report) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. Abbott Laboratories’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.51 EPS for the current year.

Abbott Laboratories Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Insider Activity In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile (Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Featured Stories Five stocks we like better than Abbott Laboratories Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEABN Amro Investment Solutions Sells 41,096 Shares of Ingersoll Rand Inc. $IR

NEXT HEADLINE »ABN Amro Investment Solutions Boosts Stake in International Business Machines Corporation $IBM

A sign marks the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023. REUTERS/Brian Snyder/File Photo Purchase Licensing Rights, opens new tab

CompaniesJuly 23 (Reuters) - Thermo Fisher Scientific (TMO.N), opens new tab beat Wall Street estimates for second-quarter ​profit and revenue on Thursday, as improving customer demand lifted ‌sales across all its business segments.

Shares of the Waltham, Massachusetts-based company were up more than 5% in premarket trading.

Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.

The life sciences tools market has ​shown signs of improvement as biotech and pharmaceutical companies ​increase spending on research and manufacturing after a prolonged ⁠post-pandemic slowdown. Thermo Fisher said customer activity across its markets ​continued to strengthen.

"Our end markets continue to strengthen and we're making ​great progress enhancing our capabilities,” CEO Marc Casper said.

Thermo Fisher’s laboratory products and biopharma services segment, which supports clinical trials and drug manufacturing, posted a ​near 12% rise in revenue to $6.69 billion.

The life-sciences solutions segment, ​which supplies products used in biological research and drug production, recorded an increase ‌of ⁠about 13% in revenue to $2.82 billion.

The company's quarterly revenue grew 10% to $11.99 billion, above analysts' estimate of $11.70 billion, according to data compiled by LSEG.

Peer Danaher (DHR.N), opens new tab also beat quarterly profit estimates and raised ​its annual profit ​outlook. However, it ⁠cut its full-year core revenue growth outlook earlier this week due to weaker respiratory testing revenue, ​and also reported lower-than-expected revenue in its biotechnology business.

The ​results ⁠should reassure investors that end markets for life-sciences tools are turning and that Danaher's bioprocessing order delay was "company-specific" and "not reflective of the industry," ⁠Evercore ISI ​analyst Vijay Kumar said.

Thermo Fisher posted ​second-quarter adjusted earnings of $6.03 per share, above analysts' average estimate of $5.71 per share.

Reporting by ​Kunal Das and Puyaan Singh in Bengaluru; Editing by Tasim Zahid

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Item 1 of 2 A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo/File Photo

[1/2]A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. REUTERS/Hollie Adams/Brendan McDermid/Combination/File Photo/File Photo Purchase Licensing Rights, opens new tab

SummaryCompaniesOverweight or obese diabetes patients had 20.8% weight loss at high dose of retatrutidePatients with severe obesity and cardiovascular disease had weight loss of 22.6% at highest doseLilly ​plans FDA biologics application in first quarter 2027July 23 (Reuters) - Eli Lilly (LLY.N), opens new tab ‌on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in ​the first quarter of next year.

Retatrutide is designed to target three different metabolic ​hormones: GLP-1, GIP and glucagon. The company's current injectable obesity drug, Zepbound, ⁠targets GLP-1 and GIP, while rival Novo Nordisk's (NOVOb.CO), opens new tab Wegovy targets just GLP-1.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

Lilly said ​an 80-week trial of adults with severe obesity and established heart disease showed average weight ​loss of 22.6% for the highest weekly dose of retatrutide.

The company said major cardiovascular events occurred less frequently than expected in both the treatment and placebo groups. But when measuring just the three ​most severe events — heart attack, stroke and death — patients on retatrutide had a 12% ​higher risk than the placebo group.

A different 80-week trial of overweight or obese patients who also had ‌type ⁠2 diabetes showed that participants given the highest dose lost 20.8% of their body weight and lowered A1C levels by 1.6%.

The most common side effects in both trials were nausea and diarrhea.

Lilly had previously announced that patients with obesity but not diabetes lost ​an average of 28.3% of ​their weight in an ⁠80-week trial of retatrutide. Positive results were also seen in Phase 3 studies of the drug's impact on knee osteoarthritis pain and ​obstructive sleep apnea.

"Across five positive Phase 3 studies, retatrutide has shown powerful ​efficacy, and ⁠we believe it could be an important future tool in the management of cardiometabolic health,” Lilly Executive Vice President Kenneth Custer said in a statement.

Lilly said it plans to submit ⁠a ​biologics license application for retatrutide to the FDA in ​the first quarter of next year. The company also said full results of the latest trials will be ​published in medical journals at a later date.

Reporting By Deena Beasley; Editing by Chris Reese

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Posted by Defense World Staff on Jul 23rd, 2026

ABN Amro Investment Solutions grew its position in shares of Texas Instruments Incorporated (NASDAQ:TXN – Free Report) by 10.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,988 shares of the semiconductor company’s stock after buying an additional 4,463 shares during the quarter. ABN Amro Investment Solutions’ holdings in Texas Instruments were worth $9,316,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in the company. Strategic Wealth Investment Group LLC purchased a new stake in Texas Instruments in the 2nd quarter valued at approximately $25,000. Portus Wealth Advisors LLC acquired a new stake in shares of Texas Instruments in the 1st quarter valued at approximately $27,000. High Point Wealth Management LLC purchased a new stake in shares of Texas Instruments in the fourth quarter valued at approximately $25,000. Advocate Investing Services LLC acquired a new position in Texas Instruments during the fourth quarter worth $25,000. Finally, Scarborough Advisors LLC purchased a new position in Texas Instruments in the first quarter worth $29,000. Institutional investors and hedge funds own 84.99% of the company’s stock.

Insider Activity In other Texas Instruments news, VP Mark T. Roberts sold 28,080 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $280.34, for a total value of $7,871,947.20. Following the sale, the vice president directly owned 53,809 shares of the company’s stock, valued at approximately $15,084,815.06. This trade represents a 34.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Mohammad Yunus sold 51,098 shares of Texas Instruments stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $270.44, for a total value of $13,818,943.12. Following the completion of the sale, the vice president owned 52,856 shares of the company’s stock, valued at $14,294,376.64. This trade represents a 49.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 303,475 shares of company stock valued at $85,666,638 in the last three months. Company insiders own 0.60% of the company’s stock.

Texas Instruments Stock Up 1.0% TXN stock opened at $294.19 on Thursday. The stock has a market capitalization of $267.74 billion, a P/E ratio of 50.38, a PEG ratio of 1.49 and a beta of 1.32. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.94 and a current ratio of 4.46. Texas Instruments Incorporated has a one year low of $152.73 and a one year high of $334.03. The company has a 50 day moving average price of $301.99 and a two-hundred day moving average price of $246.39.

Texas Instruments (NASDAQ:TXN – Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The semiconductor company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.23. Texas Instruments had a return on equity of 32.49% and a net margin of 29.11%.The company had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.26 billion. During the same period in the previous year, the firm posted $1.41 EPS. Texas Instruments’s revenue was up 22.8% on a year-over-year basis. Texas Instruments has set its Q3 2026 guidance at 2.230-2.570 EPS. As a group, sell-side analysts expect that Texas Instruments Incorporated will post 7.69 EPS for the current year.

Texas Instruments Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 11th. Investors of record on Friday, July 31st will be given a dividend of $1.42 per share. The ex-dividend date is Friday, July 31st. This represents a $5.68 annualized dividend and a yield of 1.9%. Texas Instruments’s dividend payout ratio is 97.26%.

Key Texas Instruments News Here are the key news stories impacting Texas Instruments this week:

Positive Sentiment: Texas Instruments beat Q2 earnings and revenue estimates, signaling better-than-expected operating performance. Texas Instruments Tops Q2 Earnings and Revenue Estimates Positive Sentiment: Management raised Q3 guidance above Wall Street expectations, which supports the case for an improving demand backdrop in industrial, automotive and AI-related chip markets. Texas Instruments forecasts quarterly revenue above estimates Positive Sentiment: Revenue, profit and EPS all increased year over year, showing a healthier operating trend versus the same quarter last year. Texas Instruments Posts Higher Second-Quarter Profit, Revenue as Sales Increase Neutral Sentiment: Despite the solid report, TXN weakened in after-hours trading as investors likely focused on valuation and whether the improvement is durable. Conference Call and Press Release Wall Street Analyst Weigh In TXN has been the topic of several research reports. Robert W. Baird upped their target price on Texas Instruments from $225.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, April 23rd. KeyCorp lifted their price target on Texas Instruments from $325.00 to $390.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. boosted their price objective on shares of Texas Instruments from $227.00 to $280.00 and gave the stock an “overweight” rating in a research report on Thursday, April 23rd. The Goldman Sachs Group increased their price objective on shares of Texas Instruments from $175.00 to $200.00 and gave the company a “sell” rating in a research note on Thursday, April 23rd. Finally, Wolfe Research restated an “outperform” rating and set a $315.00 target price on shares of Texas Instruments in a report on Thursday, April 23rd. Thirteen investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $290.75.

Read Our Latest Research Report on Texas Instruments

Texas Instruments Profile (Free Report)

Texas Instruments Inc (NASDAQ: TXN) is a global semiconductor company headquartered in Dallas, Texas, that designs and manufactures analog and embedded processing chips. The company’s products are used across a wide range of end markets, including industrial, automotive, personal electronics, communications and enterprise equipment. TI’s business emphasizes components that condition, convert, manage and move electrical signals—capabilities that are foundational to modern electronic systems.

TI’s product portfolio includes a broad array of analog integrated circuits—such as power management, amplifiers, data converters and interface devices—as well as embedded processors and microcontrollers used to control systems and run real-time applications.

Featured Articles Five stocks we like better than Texas Instruments Could Truth API Become Trump Media’s First Meaningful Revenue Driver? Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Moog Is More Than a Missile Maker, and Wall Street Is Noticing A Boring Dividend Growth Strategy Becomes a Solid Defensive Play Want to see what other hedge funds are holding TXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Texas Instruments Incorporated (NASDAQ:TXN – Free Report).

Receive News & Ratings for Texas Instruments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Texas Instruments and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEABN Amro Investment Solutions Makes New $5.94 Million Investment in TE Connectivity Ltd. $TEL